Why the study?
Does blood pressure-lowering treatment improve life expectancy and cost-effectiveness in hypothetical cohorts of varying age, sex, and cardiovascular risk?
Population
Hypothetical cohorts for 20 different strata of sex, age, and cardiovascular risk
Comparison
Blood pressure-lowering treatment vs Non-treatment of hypertension
Design
Other
Follow-up
lifetime
Authors
Loading...
May inform high-risk BP treatment decisions in models; leaves open prospective validation of life expectancy and cost gains.
Does blood pressure-lowering treatment improve life expectancy and cost-effectiveness in hypothetical cohorts of varying age, sex, and cardiovascular risk?
Blood pressure-lowering treatment increases life expectancy across all age and risk groups, but is most cost-effective in patients at high cardiovascular risk.
Peter Jackson (2003) studied this question.